DOCSLIB.ORG

Flight Behaviour in Humans Is Intensified by a Candidate Genetic Risk Factor for Panic Disorder: Evidence from a Translational Model of Fear and Anxiety

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Flight Behaviour in Humans Is Intensified by a Candidate Genetic Risk Factor for Panic Disorder: Evidence from a Translational Model of Fear and Anxiety Molecular Psychiatry (2010), 1–2 & 2010 Nature Publishing Group All rights reserved 1359-4184/10 $32.00 www.nature.com/mp LETTER TO THE EDITOR Flight behaviour in humans is intensified by a candidate genetic risk factor for panic disorder: evidence from a translational model of fear and anxiety Molecular Psychiatry advance online publication, 23 iourally, as the intensity of flight effort in response to February 2010; doi:10.1038/mp.2010.2 a pursuing threat stimulus.5 The genetic risk factor for PD used in this study was the C allele of the 102T/C single-nucleotide polymorphism (rs6313) within the Panic disorder (PD) is a serious and common serotonin 2a receptor gene (HTR2A) on chromosome psychiatric condition1 characterized mainly by recur- 13q14.2; the C allele in this SNP is known to be rent episodes of intense, uncontrollable fear known as associated with increased susceptibility to pure but panic attacks.2 The underlying causal mechanism for not co-morbid PD,6 as well as to increased intensity of PD is unknown;3 however, the discovery that drugs panic symptoms.7 All 200 participants (107 of whom with clinical effectiveness against PD preferentially were male) gave informed consent and self-identified alter rodent flight behaviour suggests that PD reflects as healthy Caucasians. Buccal cells were collected alterations in the brain systems that govern flight.4 and DNA extracted using established methods (see An association between PD and flight in humans Supplementary Information). is supported anecdotally by the tendency for PD The genotype distribution of rs6313 SNP in HTR2A sufferers to feel a strong urge to flee from the location was in Hardy–Weinberg equilibrium (w2 = 0.632, where a panic attack occurs.2 Here we provide the d.f. = 2, P = 0.73). There were no significant genotype first human empirical evidence for a PD–flight link, effects on flight intensity (F(1, 192) = 2.69, P = 0.070); showing that flight behaviour is significantly more however, carriers of the C risk allele showed sig- intense in carriers of a candidate genetic risk factor for nificantly greater flight intensity than TT individuals PD than in non-carriers. (F(1, 194) = 4.90, P = 0.033; Figure 1b). The construct Human flight behaviour was measured using a validity of flight intensity as a specific measure of fear computerized translation of a rodent runway task proneness was supported by its significant positive (Figure 1a) designed to index fear proneness behav- association with scores on tissue damage fear (mea- * 0.25 0.00 Flight Intensity -0.25 -0.50 TT CC & CT HTR2A Figure 1 (a) The Joystick Operated Runway Task, a computerized human translation of the Mouse Defense Test Battery. The participants used a force-sensing joystick apparatus (PH-JS1, Psyal, London, UK) to control the speed of a cursor (green dot) pursued along an on-screen runway by a threat stimulus (red dot). In order to provide aversive motivation for flight, if the red dot caught the green dot participants received an unpleasant but harmless 115-dB white noise burst lasting 250 ms. In order to mimic the calorie cost of flight in real threat situations, the velocity of the green dot was increased in proportion to the force applied to the joystick. In order to control for individual differences in strength and motivation, the minimum force required for the green dot cursor to reach the escape velocity was set at 50% of the maximum force that the participant exerted during an earlier calibration session. (b) Flight intensity was significantly increased by carrying the C allele of the 102T/C polymorphism (rs6313) within the serotonin 2a receptor gene (HTR2A; error bars represent 1 s.e.m.; *P < 0.033). Letters to the Editor 2 sured by the Fear Survey Schedule) (F(1, 194) = 5.92, studies of the present type should invert the inter- P = 0.022). The construct validity of flight intensity pretation of their results, portraying TT carriers as was also supported by the absence of a significant unusually resistant to fear or PD rather than carriers of association with scores on Spielberger trait anxiety the C allele as particularly prone to fear or PD. (F(1, 194) = 0.01, P = 0.998), which is a widely ac- cepted questionnaire measure of anxiety proneness.8 Sex did not affect flight intensity in this model Conflict of interest (F(1, 194) = 1.50, P = 0.222), nor was there a significant The authors declare no conflict of interest. allele  sex interaction (F(1, 194) = 1.56, P = 0.213). There was no significant interaction between tissue AM Perkins1, U Ettinger2,3, SCR Williams1, damage fear and rs6313 carrier status (C carrier or TT M Reuter4,5, J Hennig6 and PJ Corr7 homozygote) (F(1, 191) = 0.44, P = 0.511). 1Centre for Neuroimaging Sciences, Institute of In overview, therefore, our study is the first Psychiatry, King’s College London, London, UK; molecular genetic investigation of human defensive 2Department of Psychiatry, Ludwig-Maximilians- behaviour and the first study empirically to support University Munich, Munich, Germany; in humans the hypothesis that PD stems from 3Department of Psychology, Ludwig-Maximilians- alterations in the brain systems governing flight University Munich, Munich, Germany; behaviour. However, although the HTR2A gene on 4Department of Psychology, Laboratory of chromosome 13q4-21 has previously been asso- Neurogenetics, University of Bonn, Bonn, Germany; ciated with PD, as a caveat it should be noted 5Center for Economics and Neuroscience, that the rs6313 SNP in exon 1 of the coding sequence University of Bonn, Bonn, Germany; of the HTR2A gene is a synonymous (or silent) 6Department of Psychology, University polymorphism. Therefore, its previously observed of Gießen, Gießen, Germany and effects at the phenotypic level may be mediated 7School of Social Work and Psychology, University of not by changes in protein structure but by other East Anglia, Norwich, UK mechanisms such as gene expression. As rs6313 is E-mail: [email protected] part of a four-SNP haplotype (rs6311, rs1328674, rs6313, rs6314), future attempts at understanding the causative mechanisms underlying the asso- References ciation between the C allele in rs6313 and flight 1 Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters intensity should ultimately consider these other EE. Lifetime prevalence and age-of-onset distributions of DSM-IV linked polymorphisms.9,10 disorders in the National Comorbidity Survey Replication. Arch Although our findings suggest that PD is mediated by Gen Psychiatry 2005; 62: 593–603. the brain systems that govern flight behaviour, our 2 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM-IV) American molecular genetic design could not reveal which brain Psychiatric Association: Washington, DC, USA, 1994. systems may be implicated. In rats electrical stimulation 3 Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical of the dorsal periaqueductal grey prompts flight beha- hypothesis of panic disorder, revised. Am J Psychiatry 2000; 157: viour, suggesting that this structure may be particularly 493–505. 4 Griebel G, Blanchard DC, Agnes RS, Blanchard RJ. Differential relevant to determining susceptibility to PD. Therefore, a modulation of antipredator defensive behavior in Swiss-Webster desirable next step would be functional neuroimaging mice following acute or chronic administration of imipramine and studies using our runway task that explore brain activity fluoxetine. Psychopharmacology 1995; 120: 57–66. during flight. In addition, it would be desirable from an 5 Perkins AM, Ettinger U, Davis R, Foster R, Williams SCR, Corr PJ. individual differences perspective to explore whether Effects of Lorazepam and citalopram on human defensive reactions: ethopharmacological differentiation of fear and anxiety. participants that flee intensely and report being espe- J Neurosci 2009; 29: 12617–12624. cially prone to fear show particularly intense activity in 6 Maron E, Nikopensius T, Ko˜ks S, Altma¨e S, Heinaste E, Vabrit K the target brain systems. et al. Association study of 90 candidate gene polymorphisms in Finally, a strength of the use of healthy participants panic disorder. Psychiatr Genet 2005; 15: 17–24. 7 Yoon HK, Yang JC, Lee HJ, Kim YK. The association between in this study is that the heightened flight reactions serotonin-related gene polymorphisms and panic disorder. JAnxiety of C allele carriers cannot be easily explained as an Disord 2008; 22: 1529–1534. outcome of the acute symptomatic effects of PD or as a 8 Barnes LLB, Harp D, Jung WS. Educ Psychol Meas 2002; 62: 603–618. side effect of medication for PD, but instead may be 9 Serretti A, Calati R, Giegling I, Hartmann AM, Mo¨ller HJ, Colombo part of an inherited trait of fearfulness/flight prone- C et al. 5-HT2A SNPs and the Temperament and Character 3 Inventory. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: ness that could ultimately constitute an endopheno- 1275–1281. 11 type for PD. However, this view should be tempered 10 Serretti A, Drago A, De Ronchi D. HTR2A gene variants with the consideration that individuals without the C and psychiatric disorders: a review of current literature and allele (that is, who had the TT genotype) are relatively selection of SNPs for future studies. Curr Med Chem 2007; 14: 2053–2069. rare (only 18 male and 12 female participants in the 11 Gottesman II, Gould TD. The endophenotype concept in psychia- present sample). The minority status of the TT try: etymology and strategic intentions. Am J Psychiatry 2003; 160: individuals, therefore, implies that molecular genetic 636–645. Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp) Molecular Psychiatry.
Load more

Recommended publications
  • Gene Polymorphisms of Serotonin Receptors and Drug-Induced Hyperprolactinemia in Patients with Schizophrenia
    Poster number: P.3.b.037 Gene polymorphisms of serotonin receptors and drug-induced hyperprolactinemia in patients with schizophrenia Diana Z. Оsmanova1, Anastasia S. Boiko1, Olga Yu. Fedorenko1, Ivan V. Pozhidaev1, M.B. Freidin1 Elena G. Kornetova1, Svetlana A. Ivanova1 , Bob Wilffert2, Anton J.M. Loonen2 1. Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia 2. Department of Pharmacy, University of Groningen, Groningen, The Netherlands BACKGROUND RESULTS Antipsychotic drug-induced hyperprolactinemia is an All patients with schizophrenia were divided into two increasingly prevalent problem in current psychiatric practice and groups: those with and without hyperprolactinemia. Patients responsible for troublesome side effects like loss of libido and from both groups were genotyped for HTR1A variants: rs6295, impotence. The chance to develop hyperprolactinemia depends rs1364043, rs10042486, rs1800042, rs749099; for HTR1B: upon the pharmacological properties of antipsychotic medication rs6298, rs6296, rs130058; for HTR2A: rs6311, rs6313, rs6314, used, of its dosage and treatment duration, as well as from the rs7997012, rs1928040, rs9316233, rs2224721, rs6312; for genetic make-up and other characteristics which determine the HTR2C: rs6318, rs5946189, rs569959, rs17326429, rs4911871, individual sensitivity of the individual patient. rs3813929, rs1801412, rs12858300; for HTR3A: rs1062613, Second generation antipsychotics are (often) more potent rs33940208, rs1176713; for HTR3B:
    [Show full text]
  • Pharmacogenetics of Antidepressants, a Review Of
    al Depres ic sio lin n C Reyes-Barron et al., Clin Depress 2016, 2:2 Clinical Depression Research Article Article OpenOpen Access Access Pharmacogenetics of Antidepressants, A Review of Significant Genetic Variants in Different Populations Cynthia Reyes-Barron1, Silvina Tonarelli1, Andrew Delozier1, David F. Briones1, Brenda B. Su2, Lewis P. Rubin1 and Chun Xu1* 1Texas Tech University Health Sciences Centre, Paul L. Foster School of Medicine 2College of Medicine and Health Sciences, UAE University, Department of Internal Medicine Abstract Major depressive disorder is a highly prevalent disease that is challenging to treat, often requiring medication and dose adjustments. Genetic factors play an important role in psychotropic medication responses. However, the translation of pharmacogenetics findings to clinical recommendations with regards to antidepressant responses is still in its early stages. We reviewed recent primary research articles, meta-analyses, and reviews on the pharmacogenetics of antidepressant treatment for major depressive disorder in different populations. We identified eight genes with likely associations with treatment responses and summarized genetic variants most likely to influence treatment responses. We determined the frequency of these variants in Caucasian, Asian, Hispanic, and African American populations. The genes are related to functions in drug metabolism, transport, signalling, stress response, and neuroplasticity. Clinical recommendations already exist for CYP2D6 and CYP2C19 cytochrome P450 drug metabolism genes. The other genes are: ABCB1 with single nucleotide polymorphisms (SNPs) rs2032583 and rs2235015; FKBP5 with SNPs rs1360780, rs3800373, and rs4713916; GNB3 with SNP rs5443; BDNF with SNP rs6265; HTR2A with SNPs rs7997012 and rs6313; and SLC6A4 with polymorphisms 5-HTTLPR and STin2. There is significant variability of the frequencies of these polymorphisms in the different populations we reviewed.
    [Show full text]
  • A Serotonin Receptor with a Possible Role in Joint Diseases
    Anders Kling 5-HT2 A – a serotonin receptor with a possible role in joint diseases role with a possible receptor – a serotonin 5-HT2A – a serotonin receptor with a possible role in joint diseases Anders Kling Umeå University 2013 Umeå University Department of Pharmacology and Clinical Neuroscience New Serie 1547 Department of Pharmacology and Clinical Neurosciences Umeå University ISSN: 0346-6612 Umeå University, Sweden 2013 SE-901 87 Umeå, Sweden ISBN 978-91-7459-549-9 5-HT2A – a serotonin receptor with a possible role in joint diseases Anders Kling Institutionen för farmakologi och klinisk neurovetenskap, Klinisk farmakologi/ Department of Pharmacology and Clinical Neuroscience, Clinical Pharmacology Umeå universitet/ Umeå University Umeå 2013 Responsible publisher under swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7459-549-9 ISSN: 0346-6612 New series No: 1547 Elektronisk version tillgänglig på http://umu.diva-portal.org/ Tryck/Printed by: Print och Media, Umeå universitet Umeå, Sweden 2013 Innehåll/Table of Contents Innehåll/Table of Contents i Abstract iv Abbreviations vi List of studies viii Populärvetenskaplig sammanfattning ix 5-HT2A – en serotoninreceptor med möjlig betydelse för ledsjukdomar ix Introduction 1 The serotonin system 1 Serotonin 1 Serotonin receptors 2 The serotonin system and platelets 2 Serotonin receptor 5-HT2A 3 Localisation/expression of 5-HT2A receptors 3 Functions of the 5-HT2A receptor 4 Regulation of the 5-HT2A receptor
    [Show full text]
  • Molecular Genetics of Human Personality Traits for Psychiatric, Behav- Ioral, and Substance-Related Disorders Eugene Lin*,1 and Po See Chen*,2,3
    The Open Translational Medicine Journal, 2009, 1, 1-8 1 Open Access Molecular Genetics of Human Personality Traits for Psychiatric, Behav- ioral, and Substance-Related Disorders Eugene Lin*,1 and Po See Chen*,2,3 1Vita Genomics, Inc., 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan 2Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan 3National Cheng Kung University Hospital and Dou-Liou Branch, Taiwan Abstract: The investigation of personality genetics had received much attention since the three seminal reports showing an association between genes and personality traits in the general population. Accumulating evidences suggested that per- sonality traits have significant genetic components. Although currently available data are not enough for proof, more and more genetic variants associated with personality traits are being discovered. In this paper, we review related studies of gene polymorphisms and human personality traits for psychiatric, behavioral, and substance-related disorders. First, we briefly describe the commonly-used self-reported temperament measures that define personality dimensions. Then, we summarize the characteristics of the candidate genes for personality traits, and investigate gene variants which have been suggested to be linked with personality traits for individuals with psychiatric, behavioral, and substance-related disorders. Keywords: Molecular genetics, personality, psychiatric disorders, temperament measures. 1. INTRODUCTION and 5-HTTLPR but not other anxiety-related personality traits [14,15]. The investigation of personality genetics had received much attention since the three seminal reports [1-3] in 1996 We reviewed related studies of gene polymorphisms and showing an association between genes and personality traits human personality traits for psychiatric, behavioral, and sub- in the general population.
    [Show full text]
  • Case–Control Association Study of 59 Candidate Genes Reveals the DRD2
    Journal of Human Genetics (2009) 54, 98–107 & 2009 The Japan Society of Human Genetics All rights reserved 1434-5161/09 $32.00 www.nature.com/jhg ORIGINAL ARTICLE Case–control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population Elitza T Betcheva1, Taisei Mushiroda2, Atsushi Takahashi3, Michiaki Kubo4, Sena K Karachanak5, Irina T Zaharieva5, Radoslava V Vazharova5, Ivanka I Dimova5, Vihra K Milanova6, Todor Tolev7, George Kirov8, Michael J Owen8, Michael C O’Donovan8, Naoyuki Kamatani3, Yusuke Nakamura1,9 and Draga I Toncheva5 The development of molecular psychiatry in the last few decades identified a number of candidate genes that could be associated with schizophrenia. A great number of studies often result with controversial and non-conclusive outputs. However, it was determined that each of the implicated candidates would independently have a minor effect on the susceptibility to that disease. Herein we report results from our replication study for association using 255 Bulgarian patients with schizophrenia and schizoaffective disorder and 556 Bulgarian healthy controls. We have selected from the literatures 202 single nucleotide polymorphisms (SNPs) in 59 candidate genes, which previously were implicated in disease susceptibility, and we have genotyped them. Of the 183 SNPs successfully genotyped, only 1 SNP, rs6277 (C957T) in the DRD2 gene (P¼0.0010, odds ratio¼1.76), was considered to be significantly associated with schizophrenia after the replication study using independent sample sets. Our findings support one of the most widely considered hypotheses for schizophrenia etiology, the dopaminergic hypothesis.
    [Show full text]
  • Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT
    Braz J Psychiatry. 2019 xxx-xxx;00(00):000-000 doi:10.1590/1516-4446-2019-0620 Brazilian Psychiatric Association 00000000-0002-7316-1185 ORIGINAL ARTICLE Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial Andre R. Brunoni0000-0000-0000-0000 ,1,2 Angel Carracedo,3 Olalla M. Amigo,3 Ana L. Pellicer,3 Leda Talib,2 Andre F. Carvalho0000-0000-0000-0000 ,4 Paulo A. Lotufo,1 Isabela M. Bensen˜ or,1 Wagner Gattaz,2 Carolina Cappi5 1Departamento de Medicina Interna, Faculdade de Medicina, Universidade de Sa˜o Paulo (USP), Sa˜o Paulo, SP, Brazil. 2Laborato´rio de Neurocieˆncias (LIM-27) and Instituto Nacional de Biomarcadores em Psiquiatria (INBION), Departamento e Instituto de Psiquiatria, Faculdade de Medicina, USP, Sa˜o Paulo, SP, Brazil. 3Grupo de Medicina Xeno´mica/Pharmacogenetics Research, Laboratorio SSL1, Centro Singular de Investigacio´n en Medicina Molecular y Enfermedades Cro´nicas (CiMUS), Santiago de Compostela, Spain. 4Department of Psychiatry, Faculty of Medicine, University of Toronto & Centre for Addiction & Mental Health (CAMH), Toronto, Canada. 5Programa Transtornos do Espectro Obsessivo-Compulsivo, Departamento e Instituto de Psiquiatria, Faculdade de Medicina, USP, Sa˜o Paulo, SP, Brazil. Objective: We investigated whether single nucleotide polymorphisms (SNPs) associated with neuroplasticity and activity of monoamine neurotransmitters, such as the brain-derived neurotrophic factor (BDNF, rs6265), the serotonin transporter (SLC6A4, rs25531), the tryptophan hydroxylase 1 (TPH1, rs1800532), the 5-hydroxytryptamine receptor 2A (HTR2A, rs6311, rs6313, rs7997012), and the catechol-O-methyltransferase (COMT, rs4680) genes, are associated with efficacy of transcranial direct current stimulation (tDCS) in major depression.
    [Show full text]
  • Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment Francis J
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment Francis J. McMahon,1,* Silvia Buervenich,1,* Dennis Charney,3 Robert Lipsky,4 A. John Rush,5 Alexander F. Wilson,6 Alexa J. M. Sorant,6 George J. Papanicolaou,6 Gonzalo Laje,1 Maurizio Fava,7 Madhukar H. Trivedi,5 Stephen R. Wisniewski,8 and Husseini Manji2 1Genetic Basis of Mood and Anxiety Disorders and 2Laboratory of Molecular Pathophysiology, Mood and Anxiety Program, National Institute of Mental Health (NIMH), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda; 3Departments of Psychiatry, Neuroscience, and Pharmacology & Biological Chemistry, Mount Sinai School of Medicine, New York; 4Section of Molecular Genetics, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, NIH, DHHS, Rockville, MD; 5Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; 6Genometrics Section, Inherited Disease Research Branch, National Human Genome Research Institute, NIH, DHHS, Baltimore; 7Massachusetts General Hospital, Boston; and 8Department of Epidemiology, University of Pittsburgh, Pittsburgh Depressive disorders account for a large and increasing global burden of disease. Although the condition of many patients improves with medication, only a minority experience full remission, and patients whose condition responds to one medication may not have a response to others. Individual variation in antidepressant treatment outcome is, at present, unpredictable but may have a partial genetic basis. We searched for genetic predictors of treatment out- come in 1,953 patients with major depressive disorder who were treated with the antidepressant citalopram in the Sequenced Treatment Alternatives for Depression (STAR*D) study and were prospectively assessed.
    [Show full text]
  • In Vitro Monitoring of HTR2A-Positive Neurons Derived from Human
    www.nature.com/scientificreports OPEN In vitro monitoring of HTR2A‑positive neurons derived from human‑induced pluripotent stem cells Kento Nakai1,8, Takahiro Shiga2,8, Rika Yasuhara3, Avijite Kumer Sarkar1, Yuka Abe1, Shiro Nakamura4, Yurie Hoashi1, Keisuke Kotani1, Shoji Tatsumoto5, Hiroe Ishikawa5, Yasuhiro Go5,6,7, Tomio Inoue4, Kenji Mishima3, Wado Akamatsu2 & Kazuyoshi Baba1* The serotonin 5‑HT2A receptor (5‑HT2AR) has been receiving increasing attention because its genetic variants have been associated with a variety of neurological diseases. To elucidate the pathogenesis of the neurological diseases associated with 5‑HT2AR gene (HTR2A) variants, we have previously established a protocol to induce HTR2A‑expressing neurons from human‑induced pluripotent stem cells (hiPSCs). Here, we investigated the maturation stages and electrophysiological properties of HTR2A‑positive neurons induced from hiPSCs and constructed an HTR2A promoter‑specifc reporter lentivirus to label the neurons. We found that neuronal maturity increased over time and that HTR2A expression was induced at the late stage of neuronal maturation. Furthermore, we demonstrated successful labelling of the HTR2A‑positive neurons, which had fuorescence and generated repetitive action potentials in response to depolarizing currents and an inward current during the application of TCB‑2, a selective agonist of 5‑HT2ARs, respectively. These results indicated that our in vitro model mimicked the in vivo dynamics of 5‑HT2AR. Therefore, in vitro monitoring of the function of HTR2A- positive neurons induced from hiPSCs could help elucidate the pathophysiological mechanisms of neurological diseases associated with genetic variations of the HTR2A gene. 1,2 Serotonin is a neurotransmitter involved in many physiological functions in the brain .
    [Show full text]
  • Pharmacogenetics of Antidepressant Response
    Copyright 2007 by Eric James Peters ii ACKNOWLEDGEMENTS Knowledge is priceless. Perhaps this is because the process of acquiring it is painfully slow - entire careers and countless hours of work have been performed in hopes of adding just small pieces to our fragmented understanding of the natural world. Frustrations and setbacks abound, as experiments fail and assays stop working when needed most. But the prospect of improving human health, advancing a field, or simply being the first to know something has a certain appeal. What is clear is that knowledge cannot be pursued as a solo endeavor. I was fortunate to have the support of a tremendous group of colleagues, family and friends. Without them, I would not never made it through the process. First and foremost, I would like to thank Steve Hamilton. His guidance is the reason my graduate school career had the bright spots that it did. He has taught me that science, at its very core, is not about a single experiment or laboratory technique. Instead, it is about the pursuit of knowledge, and to be a successful scientist one cannot succumb to tunnel vision. I’ve spent many engaging hours in his office discussing such varied topics as genetics, psychiatry, and religion, and he has always encouraged any curiosity or interest that I felt a need to discuss, no matter how irrelevant it was to my thesis project. He has also taught me the art of presenting science that is both exciting and accessible to the audience, which is an invaluable tool for any independent investigator.
    [Show full text]
  • Differences and Similarities in the Serotonergic Diathesis For
    Molecular Psychiatry (2010) 15, 831–843 & 2010 Macmillan Publishers Limited All rights reserved 1359-4184/10 www.nature.com/mp ORIGINAL ARTICLE Differences and similarities in the serotonergic diathesis for suicide attempts and mood disorders: a 22-year longitudinal gene–environment study J Brezo1, A Bureau2,3,CMe´rette2,4, V Jomphe2, ED Barker5,6,7, F Vitaro5,MHe´bert8, R Carbonneau5, RE Tremblay5,9,10 and G Turecki1,10 1The McGill Group for Suicide Studies, Douglas Hospital Research Centre, McGill University, Montreal, QC, Canada; 2Centre de recherche Universite´ Laval Robert-Giffard, Quebec City, QC, Canada; 3Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada; 4Department of Psychiatry, Laval University, Quebec City, QC, Canada; 5Research Unit on Children’s Psychosocial Maladjustment, University de Montre´al, Montreal, QC, Canada; 6Social, Genetic and Developmental Psychiatry Centre (MRC), King’s College London, London, UK; 7Department of Psychology, Center for the Prevention of Youth Behavior Problems, University of Alabama, Tuscaloosa, AL, USA; 8Department of Sexology, Universite´ du Que´bec, Montreal, QC, Canada and 9International Laboratory for Child and Adolescent Mental Health Development (INSERM U669, Paris, France; University College Dublin, Ireland; University of Montreal, Canada) To investigate similarities and differences in the serotonergic diathesis for mood disorders and suicide attempts, we conducted a study in a cohort followed longitudinally for 22 years. A total of 1255 members
    [Show full text]
  • (Rs1800497), T102C (Rs6313) and His452tyr (Rs6314) with Clozapine Response in First Line Therapy Resistant Schizophrenia Patients in an Iranian Ethnic Group
    IBBJ Original Article Summer 2018, Vol 4, No 3 Pharmacogenetic Analysis of Taq1A (rs1800497), T102C (rs6313) and His452Tyr (rs6314) with Clozapine Response in First Line Therapy Resistant Schizophrenia Patients in an Iranian Ethnic Group Farzan Kheirkhah1, Maryam Mafi Golchin2, Laleh Heidari3, Haleh Akhavan-Niaki2* 1. Department of Psychiatry, Babol University of Medical Sciences, Babol, Iran. 2. Department of Genetics, Faculty of Medicine, Babol University of Medical Sciences, Babol 4717647745, Iran. 3. Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran. Submitted 24 Oct 2018; Accepted 26 Nov 2018; Published 29 Dec 2018 Pharmacogenetic studies in schizophrenia patients illustrated variable response to antipsychotic treatment. Moreover, most of patients will require long-term use of atypical antipsychotic medications which may lead to drug side effect, treatment-resistance, medication arrest, and even venture to suicide. Clozapine is the best choice in the treatment of refractory patients, although not effective in all of them and also having side effects. Therefore, any information that help to predict the outcome of each antipsychotic drug in a particular patient will be highly valuable to find the right drug for the right patient. Taq1A (rs1800497) polymorphism of dopamine receptor D2, T102C (rs6313) and His452Tyr (rs6314) polymorphisms of serotonin 2A receptor were analyzed as effective single nucleotide polymorphisms (SNPs) associated with clozapine response in schizophrenia patients in an ethnic group of Iranian population. Our data suggest that the presence of C allele for rs1800497 and rs6314 and T allele Downloaded from ibbj.org at 5:16 +0330 on Sunday September 26th 2021 for rs6313 might be helpful for determining response to clozapine in first line therapy resistant patients.
    [Show full text]
  • Use of Deep-Learning Genomics to Discriminate Healthy Individuals from Those with Alzheimer’S Disease Or Mild Cognitive Impairment
    Hindawi Behavioural Neurology Volume 2021, Article ID 3359103, 15 pages https://doi.org/10.1155/2021/3359103 Research Article Use of Deep-Learning Genomics to Discriminate Healthy Individuals from Those with Alzheimer’s Disease or Mild Cognitive Impairment Lanlan Li,1 Yeying Yang,2 Qi Zhang,1 Jiao Wang,3 Jiehui Jiang ,1 and Alzheimer’s Disease Neuroimaging Initiative4 1Institute of Biomedical Engineering, School of Communication and Information Engineering, Shanghai University, Shanghai 200444, China 2LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China 3School of Life Science, Shanghai University, Shanghai 200444, China 4Indiana University School of Medicine, Indianapolis, IN 46202, USA Correspondence should be addressed to Jiehui Jiang; [email protected] Received 14 May 2021; Accepted 11 June 2021; Published 15 July 2021 Academic Editor: Muh-Shi Lin Copyright © 2021 Lanlan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objectives. Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and the most common form of dementia in the elderly. Certain genes have been identified as important clinical risk factors for AD, and technological advances in genomic research, such as genome-wide association studies (GWAS), allow for analysis of polymorphisms and have been widely applied to studies of AD. However, shortcomings of GWAS include sensitivity to sample size and hereditary deletions, which result in low classification and predictive accuracy. Therefore, this paper proposes a novel deep-learning genomics approach and applies it to multitasking classification of AD progression, with the goal of identifying novel genetic biomarkers overlooked by traditional GWAS analysis.
    [Show full text]